ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO295

Use of Guideline-Recommended Medication Therapy in a High-Risk CKD Population in the Kidney CHAMP Trial

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 2000 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Weltman, Melanie R., UPMC, Pittsburgh, Pennsylvania, United States
  • Han, Zhuoheng, University of Pittsburgh Renal-Electrolyte Division, Pittsburgh, Pennsylvania, United States
  • Alghwiri, Alaa A., University of Pittsburgh Renal-Electrolyte Division, Pittsburgh, Pennsylvania, United States
  • Yabes, Jonathan, University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, United States
  • Lavenburg, Linda-Marie Ustaris, UPMC, Pittsburgh, Pennsylvania, United States
  • Nolin, Thomas D., University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, United States
  • Jhamb, Manisha, UPMC, Pittsburgh, Pennsylvania, United States

Use of guideline-recommended medication therapy to improve kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) is suboptimal. Kidney CHAMP is a pragmatic randomized controlled trial evaluating the effectiveness of a population health management (PHM) approach to improve CKD care. The intervention leveraged electronic health records to identify patients with CKD at high risk of progression and communicate recommendations from a nephrologist-led e-consult and pharmacist-led medication review to primary care providers (PCP) randomized to the intervention group. We compared the use of guideline-recommended medication therapy in patients in the intervention group vs patients receiving usual care per their PCP.


Eligible patients were 18-85 years with high-risk CKD and not followed by a nephrologist. Guideline-recommended medication therapy included use of ACE inhibitor (ACEi) or angiotensin II receptor blocker (ARB) if baseline urine albumin-to-creatinine ratio (UACR) ≥ 300 mg/g, moderate or high intensity statin if baseline age ≤ 75 years, and SGLT2 inhibitor (SGLT2i) and/or GLP1 receptor agonist (GLP1RA). Changes in medication use between groups were tested using logistic regression via generalized estimating equations.


Among 1596 patients enrolled, 58% were females, the mean age was 74 years, mean eGFR 37 mL/min/1.73m2, and mean UACR 410 mg/g at baseline. Comorbidities included hypertension (95%), diabetes (64%), and cardiovascular disease (78%). Over a median 18 month study period, ACEi/ARB use changed from 49% to 43% (p=0.10) vs 51% to 40% (p=0.005), statin use changed from 52% to 55% (p=0.55) vs 54% to 50% (p=0.25), and SGLT2i and/or GLP1RA use changed from 9% to 20% (p<0.001) vs 5% to 13% (p<0.001) in the intervention vs usual care groups, respectively. There was no between group difference in the change in ACEi/ARB (p=0.46), statin (p=0.12), or SGLT2i and/or GLP1RA (p=0.80) use.


A PHM approach did not improve use of guideline-recommended medication therapy in patients with high-risk CKD compared to usual care. This research supports a need to address barriers in the primary care setting, including therapeutic inertia and access to clear practice guidelines, and efforts to improve the delivery of CKD care.


  • NIDDK Support